These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33928035)

  • 1. Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients.
    Xie M; Gao XS; Ma MW; Gu XB; Li HZ; Lyu F; Bai Y; Chen JY; Ren XY; Liu MZ
    Front Oncol; 2021; 11():646073. PubMed ID: 33928035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.
    Zelic R; Garmo H; Zugna D; Stattin P; Richiardi L; Akre O; Pettersson A
    Eur Urol; 2020 Feb; 77(2):180-188. PubMed ID: 31606332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of bone scans for prostate cancer staging: Which guideline shows better result?
    Chong A; Hwang I; Ha JM; Yu SH; Hwang EC; Yu HS; Kim SO; Jung SI; Kang TW; Kwon DD; Park K
    Can Urol Assoc J; 2014 Jul; 8(7-8):E515-9. PubMed ID: 25210554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients.
    Ma MW; Gao XS; Lyu F; Gu XB; Yin H; Li HZ; Li XY; Qi X; Bai Y; Chen JY
    World J Urol; 2021 Jun; 39(6):1815-1823. PubMed ID: 32691147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.
    Zumsteg ZS; Zelefsky MJ; Woo KM; Spratt DE; Kollmeier MA; McBride S; Pei X; Sandler HM; Zhang Z
    BJU Int; 2017 Nov; 120(5B):E87-E95. PubMed ID: 28464446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
    Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?
    Grant Owens R; Loloi J; Lehman EB; Kaag MG; Raman JD; Merrill SB
    Urol Oncol; 2021 Jul; 39(7):433.e9-433.e15. PubMed ID: 33610444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy of Prostate Carcinoma: A Comparison of the Predictive Role of EAU
    Buwenge M; Deodato F; Dominsky N; Ntreta M; Cilla S; Siepe G; Alitto AR; Bisello S; Valentini V; Macchia G; Morganti AG
    Anticancer Res; 2020 Aug; 40(8):4413-4418. PubMed ID: 32727771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications.
    Diamand R; Ploussard G; Roumiguié M; Malavaud B; Oderda M; Gontero P; Fourcade A; Fournier G; Benamran D; Iselin C; Fiard G; Descotes JL; Peltier A; Simone G; Roche JB; Roumeguère T; Albisinni S
    Urol Oncol; 2021 May; 39(5):296.e1-296.e9. PubMed ID: 33041188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
    Dess RT; Suresh K; Zelefsky MJ; Freedland SJ; Mahal BA; Cooperberg MR; Davis BJ; Horwitz EM; Terris MK; Amling CL; Aronson WJ; Kane CJ; Jackson WC; Hearn JWD; Deville C; DeWeese TL; Greco S; McNutt TR; Song DY; Sun Y; Mehra R; Kaffenberger SD; Morgan TM; Nguyen PL; Feng FY; Sharma V; Tran PT; Stish BJ; Pisansky TM; Zaorsky NG; Moraes FY; Berlin A; Finelli A; Fossati N; Gandaglia G; Briganti A; Carroll PR; Karnes RJ; Kattan MW; Schipper MJ; Spratt DE
    JAMA Oncol; 2020 Dec; 6(12):1912-1920. PubMed ID: 33090219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal use of pelvic lymph node dissection: Differences in guideline adherence between robot-assisted and open radical prostatectomy.
    Schiffmann J; Larcher A; Sun M; Tian Z; Berdugo J; Leva I; Widmer H; Lattouf JB; Zorn KC; Shariat SF; Montorsi F; Graefen M; Saad F; Karakiewicz PI
    Can Urol Assoc J; 2016 Aug; 10(7-8):269-276. PubMed ID: 27878050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the Stratification of Patients With Intermediate-risk Prostate Cancer.
    Stolzenbach LF; Nocera L; Collà-Ruvolo C; Tian Z; Knipper S; Maurer T; Tilki D; Graefen M; Karakiewicz PI
    Clin Genitourin Cancer; 2021 Apr; 19(2):e120-e128. PubMed ID: 33358891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines.
    Stewart SB; Thompson RH; Psutka SP; Cheville JC; Lohse CM; Boorjian SA; Leibovich BC
    J Clin Oncol; 2014 Dec; 32(36):4059-65. PubMed ID: 25403213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving risk stratification in a community-based African American population using cell cycle progression score.
    Rayford W; Greenberger M; Bradley RV
    Transl Androl Urol; 2018 Sep; 7(Suppl 4):S384-S391. PubMed ID: 30363476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe).
    Thurtle D; Bratt O; Stattin P; Pharoah P; Gnanapragasam V
    BMC Med; 2020 Jun; 18(1):139. PubMed ID: 32539712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients.
    Xu H; Zhu Y; Dai B; Ye DW
    Asian J Androl; 2018; 20(6):551-554. PubMed ID: 30027928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification.
    Leyh-Bannurah SR; Budäus L; Zaffuto E; Pompe RS; Bandini M; Briganti A; Montorsi F; Schiffmann J; Shariat SF; Fisch M; Chun F; Huland H; Graefen M; Karakiewicz PI
    Urol Oncol; 2018 Feb; 36(2):81.e17-81.e24. PubMed ID: 29248430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.
    Tiberi D; Rodrigues G; Pickles T; Morris J; Crook J; Martin AG; Cury F; Catton C; Lukka H; Warner A; Taussky D
    Can Urol Assoc J; 2017; 11(3-4):94-100. PubMed ID: 28515807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.